Release date: 2017-08-31

Since 2016, nearly 100 medical artificial intelligence startups have been born in China. They hope to seize the opportunity of China's medical reform and grow into a large company. At the same time, some equipment companies do not want to miss this opportunity, have invested in research and development of artificial intelligence medical products, or find partners to make their equipment products more intelligent and improve the competitiveness of products.

The arterial network combed the layout of eight medical device companies in the field of artificial intelligence, to see how traditional technology combined with artificial intelligence, and the arterial network also interviewed six medical artificial intelligence companies to understand how the new medical AI startups and traditions Device manufacturers cooperate to open the market.

Medical device intelligence is the trend

With the gradual implementation of grading medical treatment and the gradual rise of domestic medical devices, medical device companies, in order to be able to share the cakes in the primary medical market, and maintain competitive advantages with other companies' products, they attach importance to equipment while paying attention to hardware quality. Intelligent, especially supporting diagnostic and screening systems, is particularly attractive for primary care institutions that lack excellent doctors.

To this end, some major equipment companies have independently developed their own hardware, and some have become smarter by working with other companies.

GE Healthcare

GE's artificial intelligence layout can be divided into two parts, one for medical imaging and the other for health care.

In medical imaging, GE's low-dose CT lung cancer screening program is the industry's first program approved by the US Food and Drug Administration (FDA). GE's early screening and early diagnosis of lung cancer is based on low-dose CT equipment, enabling accurate imaging, early detection of small nodules, and automated screening of difficult-to-recognize lung nodules to assist doctors in screening quickly and accurately .

In May 2017, GE presented their technology in lung nodule recognition to the public at CMEF in Shanghai.

In terms of health care, GE has a lot of areas. Dr. Michael Dahlweid, Chief Medical Officer of GE Healthcare Digital Solutions, said that GE is currently experimenting with multiple tasks using deep learning. These include:

Identify different types of cancer tissue cells;

Identify the most effective treatment options for patients in intensive care units;

Predict whether patients in intensive care unit are likely to have sepsis or infection;

Using ultrasound to assess a patient's heart problem;

Predict disease onset.

According to Dahlweid, artificial intelligence also helps doctors make decisions and manage vast amounts of healthcare information.

Medtronic

In January 2016, Medtronic and IBM launched a diabetes monitoring app. Committed to improving the world's 415 million adults with type 1 or type 2 diabetes.

Medtronic CEO Omar Ishrak and IBM CEO Ginni Rometty said that the Medtronics and IBM conducted a pilot project on 600 anonymous patients by analyzing these patients in Medtronic's diabetes monitoring device (insulin) The data on the pump and blood glucose monitor) to identify the signs of hypoglycemia.

By analyzing these data, IBM's Watson system can make predictions 3 hours before hypoglycemia occurs. This time can take precautions to facilitate the user's life.

Wandong Medical

At the CMEF show in 2017, Wanliyun released its artificial intelligence precision medical platform - i image. Currently, the “i Image” platform has been launched for DR screening and CT detection. According to the official introduction, i images can avoid more than 50% of omissions in some small lung nodules, and the detection accuracy is over 95%. However, Dr. Yan Ziyue from Wanli Cloud Image Platform said that “Intelligent image platform is only a tool, we provide a complete solution.” In addition to image cloud services, Wanli Cloud Platform pays more attention to intelligent processing and quality control system construction.

Anhan Medical

On April 20, 2017, Anhan Medical signed an agreement with IBM China Research Institute to conduct an exploratory collaboration in the field of capsule endoscopy medical imaging, aiming to explore the use of IBM's technology in cognitive imaging to enhance the digestive tract. The feasibility of precise screening for early disease.

Anhan Medical's cutting-edge precision capsule gastroscopic system uses capsule endoscopic robots to collect medical image data, which can collect stomach examination information with higher efficiency and lower obstacles. However, about 20,000 images produced each time, which brings new challenges to the doctors, such as data processing and accurate analysis.

In clinical applications, these massive amounts of image data are difficult to quickly diagnose by manual reading, and IBM's cognitive imaging technology may provide the key to solving this problem. The IBM China Research Institute and Anhan's Early Research Collaborative Project aims to demonstrate the use of intelligent lesion detection technology to help Anhan process billions of images generated each year, improving the accuracy and feasibility of disease screening.

Johnson

In March 2015, Johnson & Johnson announced that its surgical-centered subsidiary Ethicon will collaborate with Google on robotic surgery projects, share expertise and intellectual property, create a robot-assisted surgical platform, and develop new robots. Tools and capabilities.

The surgical procedure should be that the robot picks up the scalpel autonomously and the surgeon performs remote control operations from the computer screen.

Johnson & Johnson said that the technology can perform fine surgery on the parts of the doctor's hands that are difficult to reach, so that doctors can better control and access during the operation, and achieve accuracy, while allowing patients to minimize trauma and scars.

The two sides can be described as strong and strong, and Ethicon is good at medical equipment, and Google has a deep accumulation in robotics, big data analysis and wearable technology. In addition to collaborative research and development of robotic assisted surgery platform assisted surgery, the platform may also be used to collect and analyze data related to the surgical procedure.

Siemens

Siemens' layout in the field of artificial intelligence is also about medical imaging. According to the arterial network, Siemens Medical has a set of imaging solutions based on artificial intelligence technology - syngo.via. Syngo.via builds a large data-based clinical disease knowledge base based on massive medical literature and cases, and then constructs structured tasks including image scanning, processing, and reporting in accordance with specifications and guidelines.

Syngo.via then simulates the doctor's processing operations and knowledge calls, creating a corresponding image processing stream to achieve "smart pre-processing" and "processing as reporting." In other words, before the doctor opens the case, syngo.via can follow the relevant guidelines and consensus to automatically start multi-software parallel processing.

After the case is opened, the accurate and accurate results of the disease can be automatically presented, and the results of the multi-software processing can be combined into one report, and the reporting options of staging and grading can be embedded. These technologies enable the generation of complete, graphical, and even staging and grading reports without increasing or even reducing the doctor's working time.

Siemens Medical Devices and IBM teamed up to sign the “Five-Year Global Strategic Development Plan”. IBM aims to take advantage of Siemens' global medical device sales network and channels, as well as its connections, to enter the market-oriented applications of global healthcare and health.

Their cooperation will also help Siemens' CT or MRI equipment to transform from quantitative to qualitative. For example, if you install IBM Watson's intelligent system on Siemens CT or MRI equipment.

Fujifilm and Olympus, Japan

Fujifilm and Olympus will collaborate with a society such as doctors to develop a technology for automatically determining suspicious diseases such as gastric cancer by artificial intelligence (AI) during the examination of endoscopes. Practical application.

Fujifilm and Olympus are the world's largest medical device companies. The Japanese Society of Professional Physicians, which diagnoses the endoscope of the stomach and large intestine, will participate in an empirical study that will be implemented from 2017.

According to the data, by the end of 2017, they will collect 300,000 image data from 32 hospitals in Japan, including university hospitals in Japan, as the basis for AI judgment, and will gradually increase in the future. In addition, doctors' diagnosis results will be added. The patient's past medical history, etc. The learning technology of AI will be handled by the University of Tokyo.

In addition to working alone or in collaboration with artificial intelligence systems, working with medical artificial intelligence companies is also a way that most companies today employ.

Device companies and artificial intelligence companies are "agents"

For traditional equipment companies, the process of setting up a new department to develop products is more complicated, but in cooperation with artificial intelligence companies, they do not need to spend time, money and energy to do this, and cooperate artificially to make artificial intelligence systems. It is sold on the device to increase the competitiveness of the device.

For medical artificial intelligence companies, after product development, there are two advantages to cooperation with device manufacturers. On the one hand, the actual clinical effects of their products can be verified through scientific research cooperation.

On the other hand, most medical artificial intelligence companies are now looking for a suitable profit model. However, due to the rigor of medical treatment, the country does not have a certification standard for artificial intelligence products. Usually, the company certifies two types of medical devices or three types of medical devices according to the certification process of medical devices.

Before the certification, many companies have put the system on the equipment through cooperation with the equipment company. The equipment company only needs to go to the provincial food and drug administration for reporting, and it can be on the market without re-certification. Sales, the resulting sales profit can be divided according to the proportion of the two sides in advance to negotiate.

In addition, in this process, the artificial intelligence company also understands that it is the agent of the equipment company. If the hospital finds that the artificial intelligence company wants to experience or use artificial intelligence products, the equipment sold by the artificial intelligence company is carried out according to another ratio. Divided into.

For example, the cooperation between Xi's heterogeneity and Shanghai Chengyun Medical Equipment Co., Ltd. Xi's Heterogeneity cooperates with Shanghai Chengyun in a technology-licensed manner. They plan to launch the first artificial intelligence digestive endoscope in the world during the year. Each of Shanghai Chengyun sells an artificial intelligence endoscope device. Get a partial share from it.

The endoscope is a technology update product based on equipment that has already obtained national licenses. It does not require a complicated approval process for heart products and is expected to be approved for listing next year.

Source: Arterial network (micro signal vcbeat)

Rabies Vaccine For Human

Rabies Vaccine (Vero Cell) for Human Use, Freeze-dried is a preparation of rabies fixed virus CTN-1V inoculated into Vero cell. After cultivation by bioreactor, harvest the virus suspension; further perform the concentration, inactivation, and purification. The vaccine is formulated by adding human albumin, dextran 40 and sucrose through freeze-drying process. The freeze-dried vaccine looks like a white crisp cake which turns into a transparent liquid after reconstitution, without any preservative. Active ingredient: inactivated rabies fixed virus. Excipients: Human albumin, dextran 40, sucrose, sodium chloride, potassium chloride, potassium phosphate monobasic, dibasic sodium phosphate. Diluent for vaccine: sterile water for injection. The specification is 0.5ml/vial after reconstitution. 1 vial (0.5ml) per single human dose. The vaccine titer should be not less than 2.5IU.

Rabies Vaccine For Human,Human Freeze Rabies Vaccine,Human Rabies Vaccine Storage,Freeze Rabies Vaccine For Humans

Changchun Zhuoyi Biological Co., Ltd , https://www.zhuoyibiological.com